Bli medlem
Bli medlem

Du är här

2020-05-29

2cureX: 2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal

2cureX AB ("2cureX", NASDAQ: 2CUREX) today announces that the company
has established a new partnership agreement to support the
commercialization of IndiTreat in Portugal and Spain. The partnership
agreement will support the company's efforts to increase commercial
activities and interactions with public and private hospitals in
these markets.

2cureX is in the process of launching the IndiTreat® test in the
European market.

The distribution partnership will help position IndiTreat towards a
larger customer base and will utilize the knowledge of our
distribution partner in the Oncology networks in both Portugal and
Spain.

"Partnering with Lab52 in Portugal is an important step forward to
expand our footprint in Europe and we see a great opportunity to
broaden our exposure to customers and use their knowledge of specific
networks within Cancer care" says Maarten van der Linden, Chief
Business Officer 2cureX and he continues; "I really look forward to
this collaboration, it feels very good that we are making so much
progress"

"We at Lab52 believe that the partnership established with 2cureX in
its journey to expand the concept of FPM among physicians, and to be
able to provide them, and cancer patients with the new IndiTreat
state of the art technology, will mean the beginning of a new era in
the treatment of certain types of cancer in Portugal and Spain. We
are looking forward to a very strong, and successful collaboration
between the two companies" says Armindo Silva, CEO Lab52 Portugal

IndiTreat® capitalizes on a clear market need to go beyond classical
genomic testing when tailoring cancer treatment for the individual
patient. The IndiTreat test can fill this void by providing
functional information on how available drug treatments directly
influence the patient's tumor. The IndiTreat test identifies the drug
treatment to which the individual patient is sensitive and just as
important, to which treatment the patient is resistant.

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Email: ca@skmg.se
Phone: +46 11 32 30 732

This information is information that 2cureX AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact
person set out above, on May 29th, 2020.

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test.
IndiTreat® establishes thousands of 3D micro-tumours that are similar
to the patient's tumour and identifies the treatment that most
effectively kills the patient's tumor. Immediately after the test,
the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in
colorectal cancer, ovarian cancer, pancreatic cancer, and preventive
cancer medicine. The clinical programs are conducted at major cancer
hospitals in Denmark, Germany, and United Kingdom.

IndiTreat® is presently being introduced into the European market
through an Early Access Program.

The aspiration is that IndiTreat® becomes a standard tool in Precision
Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in
Stockholm (symbol "2CUREX").

-----------------------------------------------------------
https://news.cision.com/se/2curex/r/2curex-moves-forward-with-the-commer...
https://mb.cision.com/Main/16432/3122348/1255403.pdf

Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.